[1] Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266-82. https://doi.org/10.1038/s41580-020-00324-8. [2] Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduct Target Ther. 2024;9(1):271. https://doi.org/10.1038/s41392-024-01969-z. [3] Li H, Sun Y, Yao Y, Ke S, Zhang N, Xiong W, et al. Usp8-governed GPX4 homeostasis orchestrates ferroptosis and cancer immunotherapy. Proc Natl Acad Sci U S A. 2024;121(6):e2315541121. https://doi.org/10.1073/pnas.2315541121. [4] Sun R, Yan B, Li H, Ding D, Wang L, Pang J, et al. Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. Cancer Res. 2023;83(19):3192-204. https://doi.org/10.1158/0008-5472.Can-23-0285. [5] Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-72. https://doi.org/10.1016/j.cell.2012.03.042. [6] Yang L, Cao LM, Zhang X, Chu B. Targeting ferroptosis as a vulnerability in pulmonary diseases. Cell Death Dis. 2022;13(7):649. https://doi.org/10.1038/s41419-022-05070-7. [7] Sokol KH, Lee CJ, Rogers TJ, Waldhart A, Ellis AE, Madireddy S, et al. Lipid availability influences ferroptosis sensitivity in cancer cells by regulating polyunsaturated fatty acid trafficking. Cell Chem Biol. 2025;32(3):408-22. https://doi.org/10.1016/j.chembiol.2024.09.008. [8] Liang D, Minikes AM, Jiang X. Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell. 2022;82(12):2215-27. https://doi.org/10.1016/j.molcel.2022.03.022. [9] Lv D, Shi Y, Kou L, Zhang D, Guo Y, Zhao S. Precision targeting of androgen receptor-ferroptosis crosstalk in prostate cancer: from mechanisms to therapeutic strategies. Pharmacol Res. 2025;219:107915. https://doi.org/10.1016/j.phrs.2025.107915. [10] Kumar S, Stokes J, Singh UP, Scissum Gunn K, Acharya A, Manne U, et al. Targeting Hsp70: a possible therapy for cancer. Cancer Lett. 2016;374(1):156-66. https://doi.org/10.1016/j.canlet.2016.01.056. [11] Yin L, Dai Y, Wang Y, Liu S, Ye Y, Fu Y, et al. A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells. Oncogene. 2025;44(21):1567-77. https://doi.org/10.1038/s41388-025-03328-w. [12] Wang RY, Noddings CM, Kirschke E, Myasnikov AG, Johnson JL, Agard DA. Structure of Hsp90-Hsp70-Hop-GR reveals the Hsp90 client-loading mechanism. Nature. 2022;601(7893):460-4. https://doi.org/10.1038/s41586-021-04252-1. [13] Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, et al. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018;9(1):4700. https://doi.org/10.1038/s41467-018-07178-x. [14] Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537-49. https://doi.org/10.1038/nrc2887. [15] Li L, Lu J, Fu S, Li W, Wang Y, Wang K, et al. Evodiamine induces ferroptosis in prostate cancer cells by inhibiting TRIM26-mediated stabilization of GPX4. Chin Med. 2025;20(1):71. https://doi.org/10.1186/s13020-025-01130-0. [16] Xu A, Xie Y, Han R, Zhong J, Wang Q, Zhou Q. Dihydrochelerythrine induced ferroptosis via glutathione peroxidase 4 downregulation in prostate cancer cells. Chem Biodivers. 2025;22(11):e00968. https://doi.org/10.1002/cbdv.202500968. [17] Hu F, Sun Y, Zhang Y, Chen J, Deng Y, Li Y, et al. Maslinic acid induces autophagy and ferroptosis via transcriptomic and metabolomic reprogramming in prostate cancer cells. Front Pharmacol. 2024;15:1453447. https://doi.org/10.3389/fphar.2024.1453447. [18] Zhang Y, Liu C, Yang Y, Ren H, Ren T, Huang Y, et al. TRIB3 inhibition by palbociclib sensitizes prostate cancer to ferroptosis via downregulating SOX2/SLC7A11 expression. Cell Death Discov. 2024;10(1):425. https://doi.org/10.1038/s41420-024-02152-7. [19] Cheng B, Wang Q, Li Z, Luo T, Xie J, Singh S, et al. Induction of ferroptosis in prostate cancer by CCDC7(19-13) via TRIM21-mediated ubiquitination of SLC7A11. Cell Death Differ. 2025. https://doi.org/10.1038/s41418-025-01580-x. [20] Wu Z, Su M, Chen H, Chen X, Chen CY, An L, et al. Sinularin exerts anti-cancer effects by inducing oxidative stress-mediated ferroptosis, apoptosis, and autophagy in prostate cancer cells. Anticancer Agents Med Chem. 2023;23(12):1457-68. https://doi.org/10.2174/1871520623666230331083744. [21] Liu S, Tao Y, Wu S, Lin J, Fu S, Lu J, et al. Sanguinarine chloride induces ferroptosis by regulating ROS/BACH1/HMOX1 signaling pathway in prostate cancer. Chin Med. 2024;19(1):7. https://doi.org/10.1186/s13020-024-00881-6. [22] Poli A, Finore I, Romano I, Gioiello A, Lama L, Nicolaus B. Microbial diversity in extreme marine habitats and their biomolecules. Microorganisms. 2017;5(2):25. https://doi.org/10.3390/microorganisms5020025. [23] Malik MS, Alsantali RI, Jassas RS, Alsimaree AA, Syed R, Alsharif MA, et al. Journey of anthraquinones as anticancer agents - a systematic review of recent literature. RSC Adv. 2021;11(57):35806-27. https://doi.org/10.1039/d1ra05686g. [24] Wang H, Bu L, Wang C, Zhang Y, Zhou H, Zhang X, et al. The Hsp70 inhibitor 2-phenylethynesulfonamide inhibits replication and carcinogenicity of Epstein-Barr virus by inhibiting the molecular chaperone function of Hsp70. Cell Death Dis. 2018;9(7):734. https://doi.org/10.1038/s41419-018-0779-3. [25] Jiang Y, Liu X, Sun M. The mist of ferroptosis: the Orpheus journey of mitochondria—exploring the symphony of cell fate. Int J Biol Macromol. 2025;319(2):145472. https://doi.org/10.1016/j.ijbiomac.2025.145472. [26] Wang X, Wei T, Luo J, Lang K, Song Y, Ning X, et al. Iron overload-dependent ferroptosis aggravates LPS-induced acute lung injury by impairing mitochondrial function. Inflammation. 2024;47(6):2013-26. https://doi.org/10.1007/s10753-024-02022-5. [27] Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C. Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci. 2022;24(1):449. https://doi.org/10.3390/ijms24010449. [28] Belavgeni A, Tonnus W, Linkermann A. Cancer cells evade ferroptosis: sex hormone-driven membrane-bound O-acyltransferase domain-containing 1 and 2 (MBOAT1/2) expression. Signal Transduct Target Ther. 2023;8(1):336. https://doi.org/10.1038/s41392-023-01593-3. [29] Liang D, Feng Y, Zandkarimi F, Wang H, Zhang Z, Kim J, et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell. 2023;186(13):2748-64. https://doi.org/10.1016/j.cell.2023.05.003. [30] Bochen F, Subedi S, La Manna F, Jarrin S, Papapostolou I, Kruithof-de Julio M, et al. TRPM4 contributes to cell death in prostate cancer tumor spheroids, and to extravasation and metastasis in a zebrafish xenograft model system. Mol Oncol. 2025;19(5):1299-309. https://doi.org/10.1002/1878-0261.13795. [31] Yogodzinski C, Harris JS, Lane TR, Barnes M, Vignaux PA, Raman R, et al. Machine learning modeling of zebrafish toxicity endpoints after exposure to PROTACs. Toxicol Sci. 2025. https://doi.org/10.1093/toxsci/kfaf162. [32] Chen L, Han L, Mao S, Xu P, Xu X, Zhao R, et al. Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer. Eur J Med Chem. 2021;216:113307. https://doi.org/10.1016/j.ejmech.2021.113307. [33] Aripaka K, Gudey SK, Zang G, Schmidt A, Ahrling SS, Österman L, et al. TRAF6 function as a novel co-regulator of Wnt3a target genes in prostate cancer. EBioMedicine. 2019;45:192-207. https://doi.org/10.1016/j.ebiom.2019.06.046. [34] Hu C, Sun L, Chen J, Lyu Z, Yuan C, Jiang X. Advantages of the zebrafish tumor xenograft model: the evaluation of efficacy in cancer therapy and the application to the study of lncRNAs. Front Immunol. 2024;15:1483192. https://doi.org/10.3389/fimmu.2024.1483192. [35] Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9(1):55. https://doi.org/10.1038/s41392-024-01769-5. [36] Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381-96. https://doi.org/10.1038/s41568-022-00459-0. [37] Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30(2):146-62. https://doi.org/10.1038/s41422-019-0263-3. [38] Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81(6):1583-94. https://doi.org/10.1158/0008-5472.Can-20-3477. [39] Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18(6):345-60. https://doi.org/10.1038/nrm.2017.20. [40] Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107-25. https://doi.org/10.1038/s41422-020-00441-1. [41] Ferguson ID, Lin YT, Lam C, Shao H, Tharp KM, Hale M, et al. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. Cell Chem Biol. 2022;29(8):1288-302. https://doi.org/10.1016/j.chembiol.2022.06.010. [42] Wisniewska M, Karlberg T, Lehtiö L, Johansson I, Kotenyova T, Moche M, et al. Crystal structures of the ATPase domains of four human Hsp70 isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B’, and HSPA5/BiP/GRP78. PLoS ONE. 2010;5(1):e8625. https://doi.org/10.1371/journal.pone.0008625. |